ProfileGDS5678 / 1417931_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 70% 75% 74% 77% 77% 73% 76% 80% 75% 75% 75% 75% 75% 73% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.3286270
GSM967853U87-EV human glioblastoma xenograft - Control 24.936575
GSM967854U87-EV human glioblastoma xenograft - Control 34.8151274
GSM967855U87-EV human glioblastoma xenograft - Control 45.4437477
GSM967856U87-EV human glioblastoma xenograft - Control 55.2495977
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.6414373
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.9588776
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.6043480
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.9553775
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.9613475
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.9959675
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.9867975
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.9334175
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.7329573